Onsdag 30 Oktober | 09:24:51 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-10-22 - Kvartalsrapport 2025-Q3
2025-07-18 - Kvartalsrapport 2025-Q2
2025-04-29 - Kvartalsrapport 2025-Q1
2025-04-29 - Årsstämma
2025-02-13 - Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2024-05-22 - Årsstämma
2024-05-02 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-06-02 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2023-06-02 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-03-24 - Extra Bolagsstämma 2023
2023-03-08 - Bokslutskommuniké 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-10-03 - Extra Bolagsstämma 2022
2022-08-24 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2022-06-02 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-03-09 - Bokslutskommuniké 2021
2021-11-26 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Vimian Group är en koncern verksamma inom djurhälsa. Bolaget levererar via sina dotterbolag läkemedel och tekniska lösningar till veterinärer, laboratorier och husdjursägare. Produkterna inkluderar exempelvis läkemedel med tillhörande klinisk forskning samt digitala plattformar för veterinärkliniker. Bolaget är verksamma på en global nivå med huvudkontor i Stockholm.
2024-03-08 07:30:00

The Board of Directors of Vimian AB (publ) has today adopted new financial targets. Since the previous financial targets were set three years ago, Vimian has more than doubled its revenues and adjusted EBITA through strong organic growth and 32 value-creative acquisitions that have strengthened the Company’s market positions in attractive niches of the animal health market and changed the composition and profile of the Company.

Vimian’s new financial targets

  • Adjusted EBITA above EUR 300m by 2030.
  • Net debt in relation to pro-forma adjusted LTM EBITDA shall not exceed 3.0x, subject to flexibility to fund acquisitions (unchanged).

Vimian aims to deliver adjusted EBITA above EUR 300m by 2030, and more than half of the adjusted EBITA growth should be organic. The target is not contingent on further capital injections.
The new target shall be achieved through:

  • Double-digit organic revenue growth,
  • Like-for-like adjusted EBITA margin increase,
  • Improved cash generation,
  • Value-creative acquisitions to complement existing offering, enter new geographies or gain access to new services and technologies.

“The new financial target of adjusted EBITA above EUR 300m by 2030 reflects Vimian’s ambition to build shareholder value through strong profit growth with a high level of cash generation. Vimian’s strategy remains the same, we will continue to strengthen our global market positions in selected niches of the animal health market with unmet medical needs and sustainable above market growth potential”, says Patrik Eriksson, CEO Vimian Group.
 
Previous financial targets
 

  • Vimian shall achieve a sales CAGR of at least 30 per cent in the medium term of which organic sales growth exceeds 15 per cent annually.
  • Vimian shall achieve an adjusted EBITA margin of approximately 35 per cent in the medium term and an annual adjusted EBITA above EUR 200 million in 2025.
  • Net debt in relation to pro-forma Adjusted LTM EBITDA shall not exceed 3.0x, subject to flexibility to fund acquisitions.

 
Telephone conference
 
An audiocast with CEO Patrik Eriksson and CFO Carl-Johan Zetterberg Boudrie will be organised for investors, analysts and media at 08.30 (CET) today 8 March, 2024.

To attend the teleconference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference/user ID to access the conference. You can ask questions verbally via the teleconference.
https://conference.financialhearings.com/teleconference/?id=5009822

To attend the webcast:
https://ir.financialhearings.com/investorcall

The Board of Directors of Vimian Group AB (publ)